SCHEMBL9892836

SCHEMBL9892836

CC(C)(C)OC(=O)N1CC[C@H]1C(=O)Nc1nc(C(C)(C)C)co1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LMNA P02545 1/20 0.47
NPSR1 Q6W5P4 1/20 0.47
L3MBTL1 Q9Y468 2/20 0.47
NPC1 O15118 2/20 0.47
MEN1 O00255 2/20 0.45
KMT2A Q03164 2/20 0.45
USP30 Q70CQ3 1/20 0.43
SCN4A P35499 1/20 0.41
KDM4E B2RXH2 3/20 0.40
POLB P06746 3/20 0.40
ALDH1A1 P00352 1/20 0.40
JAK2 O60674 1/20 0.39
SCN5A Q14524 1/20 0.39
SCN3A Q9NY46 1/20 0.39
RAB9A P51151 1/20 0.39
CYP1A2 P05177 1/20 0.38
CYP3A4 P08684 1/20 0.38
CYP2C19 P33261 1/20 0.38
SMN1; SMN2 Q16637 1/20 0.38
PTPN2 P17706 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16238478 0.93 LMNA (0.53) LMNANPSR1L3MBTL1NPC1MEN1
SCHEMBL16238476 0.93 LMNA (0.53) LMNANPSR1L3MBTL1NPC1MEN1
SCHEMBL9892876 0.79 ATAD2 (0.59) LMNANPSR1L3MBTL1NPC1MEN1
SCHEMBL20458254 0.78 GRM5 (0.36) LMNANPSR1L3MBTL1NPC1MEN1
SCHEMBL9892869 0.78 CNR2 (0.59) LMNANPSR1L3MBTL1NPC1MEN1
SCHEMBL9892918 0.76 LMNA (0.50) LMNANPSR1L3MBTL1NPC1MEN1
SCHEMBL2123446 0.75 CNR2 (0.62) CNR2
SCHEMBL2123439 0.75 CNR2 (0.62) CNR2
SCHEMBL16253077 0.74 CNR2 (0.62) CNR2
SCHEMBL18562254 0.73 LMNA (0.52) LMNANPSR1L3MBTL1NPC1MEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2443107-B1 AZETIDINE 2 -CARBOXAMIDE DERIVATIVES WHICH MODULATE THE CB2 RECEPTOR BOEHRINGER INGELHEIM INT (DE) 2018-08-08 EP disclosed
US-8383615-B2 Azetidine 2-carboxamide derivatives which modulate the CB2 receptor BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2013-02-26 US disclosed
US-20120142666-A1 Azetidine 2-Carboxamide Derivatives Which Modulate The CB2 Receptor BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2012-06-07 US disclosed
WO-2010147791-A1 AZETIDINE 2 -CARBOXAMIDE DERIVATIVES WHICH MODULATE THE CB2 RECEPTOR BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2010-12-23 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120142666-A1 Azetidine 2-Carboxamide Derivatives Which Modulate The CB2 Receptor CNR2, CNR1, OPRL1 LMNA 4544/4885NPSR1 149/4885L3MBTL1 4866/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.